Literature DB >> 6609197

Phenotypic and functional characterization of T cell clones derived from the cerebrospinal fluid of multiple sclerosis patients.

D Santoli, E C Defreitas, M Sandberg-Wollheim, M K Francis, H Koprowski.   

Abstract

We describe here T cell cultures and clones established from the cerebrospinal fluid (CSF) of three patients with multiple sclerosis (MS) and one chronic meningitis patient with pleocytosis. Most of the cultures were activated with phytohemagglutinin (PHA) before growth in mitogen-free interleukin 2 (IL 2), and were never restimulated. Some of the clones obtained have been propagated for over 1 yr and are strictly IL 2-dependent. Immunofluorescence analysis performed with various monoclonal antibodies revealed that the CSF-derived lines had the characteristics of activated T cells with a stable expression of either suppressor/cytotoxic or helper/inducer surface antigens. Most of the clones established had a predominantly suppressor phenotype (OKT8+), except for the clones derived from one MS patient, which expressed only the helper phenotype (anti-Leu-3a+). Consistent with these data, the CSF-derived cultures displayed a variety of immunoregulatory functions, such as the ability to lyse nonspecific and PHA-stimulated target cells, to produce IL 2 upon mitogenic activation, and to modulate polyclonally induced Ig responses. The availability of long-term CSF T cell cultures derived from MS patients at various disease stages might provide a useful tool in investigating the factor(s) involved in the etio-pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609197

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Maintenance of antigen specificity by human interleukin-2-dependent T cell lines. Use of antigen-presenting cells and OKT3 antibody in the absence of antigen.

Authors:  S J Padula; M K Pollard; E G Lingenheld; R B Clark
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

2.  B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes.

Authors:  L Matera; R Foa; M Massaia; M Giovarelli; F Veglia; A Cesano; P Lusso; A Piazza; D Santoli
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

3.  Development and characterisation of T lymphocyte lines from human small intestinal biopsies.

Authors:  D Kelleher; M F Kagnoff
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

4.  Detecting immunoglobulin abnormalities in the cerebrospinal fluid (CSF): which methods are best for clinical purposes?

Authors:  M A Laurenzi; L Provinciali; A R Giovagnoli; V Busco Bocchini; L Paris; F Chiodi
Journal:  Ital J Neurol Sci       Date:  1987-06

5.  Effect of lymphocytapheresis plus cyclophosphamide on the course of a chronic progressive form of multiple sclerosis.

Authors:  S Ferla; G Meneghetti; S Spartà; M Belloni; G Ongaro
Journal:  Ital J Neurol Sci       Date:  1985-09

6.  Suppression of interleukin 2-dependent human T cell growth in vitro by prostaglandin E (PGE) and their precursor fatty acids. Evidence for a PGE-independent mechanism of inhibition by the fatty acids.

Authors:  D Santoli; P D Phillips; T L Colt; R B Zurier
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

7.  Analysis of T-cell cultures and clones from a patient with classic rheumatoid arthritis--evidence for the existence of autoreactive T-cell clones in blood and synovial fluid.

Authors:  M Schlesier; C Ramb-Lindhauer; M Gärtner; H H Peter
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

8.  A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells.

Authors:  D Santoli; D J Tweardy; D Ferrero; B L Kreider; G Rovera
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.